The European Medicines Agency has started a real-time review of the Sanofi/GlaxoSmithKline COVID-19 vaccine. The companies hope to secure approval by the end of 2021. (Reuters)

Several U.S. states are sitting on millions of extra COVID-19 vaccine doses that will soon expire. Some state health departments have asked the White House for permission to send their surplus doses to other countries, which are struggling to vaccinate their populations. (STAT)

Relmada Therapeutics will pay $15 million upfront to acquire Arbormentis’ psilocybin and derivate program. Relmada plans to develop psychedelic therapies for depression and psychiatric disorders. (Endpoints News)

Johnson & Johnson and several other pharma distributors are close to a $26 billion agreement with states to settle thousands of lawsuits over the opioid epidemic. The settlement funds would help pay for addiction services in the U.S. (The New York Times)

New Jersey Gov. Phil Murphy urged more Americans to get vaccinated and said he would bring back mask mandates if needed. The U.S. is currently experiencing an uptick in infections in areas with low vaccination rates. (CNBC Weekly)